• About
  • About CANNT
  • Major Activities
  • Board of Directors and Contacts
  • Current Bylaws
  • Why should I become a member?
    • Fact Sheet on Representation
    • Fact Sheet on Liaisons
  • Join CANNT
• CANNT Journal
  • CANNT Journal
    • 2010
    • 2009
    • 2008
    • 2007
    • 2006
    • 2005
    • 2003
    • 2002
    • 2004
    • 2001
    • 2000
  • Download Journals
  • Information for Advertisers
  • Guidelines For Authors
  • Library/Institutional Rates
• Standards of Practice
  • Standards of Nursing Practice
  • Standards of Technical Practice
• Events
  • Calendar
  • CANNT / ACITN 2010
• Education
  • Certification
  • CNeph(C) Prep Course Presented at CANNT 2009
  • CEU Tests
  • ABSTRACTS 101 - Workshop Materials
• Resources
  • Career Opportunities (Last posting: July 19, 2010)
    • Advertisers
  • CANNT Awards, Bursaries & Grants
    • CANNT Bursaries & Grants
    • Excellence in Practice Awards
  • Amgen Canada Travel, Research & Preceptorship/Mentorship Grants Program
    • Grant Review Committee Assessment Guide
  • Internet Links
• Members
  • Renew Membership
  • CKD Review Modules
  • Change Password
  • Change Contact Info
  • CEU Tests
  • Purchase Tokens
  • Regional Reports
    • Western Region
    • Ontario
    • Quebec
    • Atlantic
    • Technical
  • Award Winners
  • Educational Opportunities
  • Refined Clinical Practice Groups (RCPGs)
    • RALNO
    • CHAC
  • My Profile

13_4_3

Volume 13, Number 4, pages 34 - 38

Proteinuria, a modifiable risk factor: Angiotensin converting enzyme inhibitors (ACEIs) and Angiotensin II receptor blockers (ARBs)

1.5 CE Hrs for Quiz

Jennifer Dykeman-Sharpe, BSc Pharm

Abstract

Microalbuminuria and proteinuria have been determined to be modifiable risk factors for the progression of chronic kidney disease as well as risk factors for cardiovascular events. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers have been demonstrated to decrease proteinuria at all stages and slow the progression of renal disease. Proteinuria can be used as a marker of successful treatment in patients with chronic kidney disease in combination with other established targets. This article discusses the various diagnostic tests used for the detection of microalbuminuria and proteinuria and appropriate pharmaceutical treatment.

Author Affiliation(s):  Jennifer Dykeman-Sharpe, BSc Pharm is Renal Pharmacist, Clinical Coordinator, Pharmacy Services, Atlantic Health Sciences Corporation, Saint John, New Brunswick.